Sanofi Genzyme Virtual Satellite Symposium
How to Optimize the Treatment Sequence in Relapsed and Refractory Multiple Myeloma Patients – Evidence-Based Medicine
October 4, 2020
12:30 – 14:00
(CEST)
| Program Chairs: Mohamad Mohty (France) and Hermann Einsele (Germany) |
|
| 12:30 – 12:35 | Welcome & Introduction Mohamad Mohty (Paris, France) & Hermann Einsele (Würzburg, Germany) |
| 12:35 – 12:50 | First line treatment options and how they impact the following treatment decisions Thierry Facon (Lille, France) |
| 12:50 – 13:05 | The role of Pomalidomide in the treatment of Lenalidomide-refractory multiple myeloma Maria Victoria Mateos (Salamanca, Spain) |
| 13:05 – 13:20 | AntiCD38 antibody therapy in Lenalidomide-Refractory Multiple Myeloma patients: evidence-based therapy considerations Philippe Moreau (Nantes, France) |
| 13:20 – 13:35 | Health-related quality of life in patients with relapsed/refractory multiple myeloma Kwee Yong (London, UK) |
| 13:35 – 14:00 | Q&A and Panel discussion Moderators: Mohamad Mohty & Hermann Einsele Panel: Thierry Facon, Maria Victoria Mateos, Philippe Moreau, Kwee Yong |